Welcome to In Cell Art
|
The sequencing of the human genome continues to reveal the genetic basis for numerous diseases leading to the identification of macromolecular drugs (DNA, RNAi, peptides, proteins) that would have a significant impact on human health. With this wealth of information the ability to design patient-specific drugs that alter the cellular machinery in a way that controls or treats a specific disease will increasingly become a reality.Designing macromolecular drugs as well as engineering novel delivery vectors that effectively transport macromolecular drugs provides an opportunity to enhance the understanding of disease mechanisms and may help treat these diseases.
In-Cell-Art has developed cutting edge nanocarriers that actively transport macromolecules into cells. In-Cell-Art is motivated by the widespread applications for the human health. By B. Pitard |
Collaborations and publications
Dec 08, 2008: In Cell Art nanospheres as novel tools for engineering biological pacemaker by intraventricular gene transfer are published in Molecular Therapy
Oct 08, 2008: In Cell Art nanocapsules, designed for hepatocyte-targeted DNA delivery, are published in the Journal of Gene medecine
Sept 08, 2008: In Cell Art and Sanofi Pasteur enter into research collaboration agreement for the evaluation of In Cell Art technologies
April 04, 2008 : In Cell Art is proud to be associated with the recent publication in Human Gene Therapy of promising results on innovative delivery systems for therapeutic protein expression
News
In Cell Art Art will be associated to the annual meeting of the Vectorisation Research Group to be held in Angers in december.
At this occasion, In Cell Art will present its activities and services during a special session dedicated to company presentations.
At this occasion, In Cell Art will present its activities and services during a special session dedicated to company presentations.
WORLD VACCINE CONGRESS 2008 : IN CELL ART will be associated with the Europe's largest and most influential vaccine congress that celebrates this year its 10th birthday.
IN CELL ART is pleased to be associated, as a sponsor, to the final symposium of the European RIGHT research project dedicated to the development of the vast potential of RNAi to provide effective therapeutic tools for the treatment of severe diseases.
www.rightsymposium2008.eu/symposium2008.html
www.rightsymposium2008.eu/symposium2008.html
Our products
ICAFectin™ 441 for DNAThe reagent of choice for primary and stem cells DNA transfection
Product informations
ICAFectin™ 442 for siRNAHighly efficient gene silencing with very few siRNA quantities
Product information
ICAVaxFectinGenetic immunization: from gene to antibody
Your Solution for DNA-based antibody generation
